Enbrel, which markets Amgen in the United States under an agreement with Pfizer, remains Amgen`s best-selling drug. Amgen discovers, develops, produces and provides innovative medicines for the human therapist. As a pioneer of biotechnology since 1980, Amgen was one of the first companies to realize the promise of the new science by bringing safe and effective drugs from the laboratory to the patient through the production plant. Amgen therapeutic drugs have changed the practice of medicine and helped millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone diseases and other serious diseases. With a deep and wide pipeline of potential new drugs, Amgen continues to promote science to dramatically improve people`s lives. To learn more about our groundbreaking science and essential medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen. Pfizer ($PFE) and Amgen ($AMGN) sort responsible tasks and people, through Enbrel, while resolving a North American marketing agreement. Amgen takes the promotion of the anti-inflammatory drug blockbuster.

At Pfizer, we use science and our global resources to improve health and well-being at every stage of life. We strive to set standards of quality, safety and value in the discovery, development and manufacture of medicines for humans and animals. Our diversified global healthcare portfolio includes small human and veterinary and human medicines and molecular vaccines, as well as nutritional products and many of the world`s best-known consumer products. Every day, in developed and emerging markets, Pfizer colleagues work to promote well-being, prevention, treatments and cures that defy the most feared diseases of our time. In keeping with our responsibility as the world`s leading biopharmaceutical company, we also cooperate with health care providers, governments and local communities to support and expand access to reliable and affordable health care around the world. For more than 150 years, Pfizer has been working to make a difference for everyone who relies on us. To learn more about our commitments, please visit us at www.pfizer.com. In North America, Etanercept is marketed by Amgen under the trade name Enbrel in two distinct formulations, one powdered, the other in the form of premeditated liquid. Wyeth (now part of Pfizer) was the only distributor of Enbrel outside Of North America, with the exception of Japan, where Takeda Pharmaceuticals markets the drug. In addition, in clinical remission IM 28 (DAS28<2.6) HAQ < 0.5.50/50/70 and the European League Against Rheumat (EULAR), a significantly higher percentage of patients was: these secondary criteria were significantly higher in the ENBREL treatment groups than in the MTX-alone group (P<0.05). Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced the results of the second and final phase of the PRESERVE study.

PRESERVE is a two-month multicenter study in patients with moderately active rheumatoid arthritis (RA) in derenBREL (LDA) 28 Low Disease Activity (LDA) or in clinical remission at En ® (Etanercept) plus methotrexate (MTX) during Phase 1 and were randomized to continue on ENBREL plus MTX or MTX for two periods. Results from the second period showed that the percentage of patients who maintained LDA or received clinical remission at week 88 was significantly higher in patients receiving ENBREL plus MTX than in patients with MTX alone. These results were accepted when the poster was presented at the American College of Rheumatology Annual Scientific Meeting 2011 in Chicago starting in November.